Literature DB >> 19913272

The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion.

Claire Y-H Huang1, Siritorn Butrapet, Kelly J Moss, Thomas Childers, Steven M Erb, Amanda E Calvert, Shawn J Silengo, Richard M Kinney, Carol D Blair, John T Roehrig.   

Abstract

The flaviviral envelope (E) protein directs virus-mediated membrane fusion. To investigate membrane fusion as a requirement for virus growth, we introduced 27 unique mutations into the fusion peptide of an infectious cDNA clone of dengue 2 virus and recovered seven stable mutant viruses. The fusion efficiency of the mutants was impaired, demonstrating for the first time the requirement for specific FP AAs in optimal fusion. Mutant viruses exhibited different growth kinetics and/or genetic stabilities in different cell types and adult mosquitoes. Virus particles could be recovered following RNA transfection of cells with four lethal mutants; however, recovered viruses could not re-infect cells. These viruses could enter cells, but internalized virus appeared to be retained in endosomal compartments of infected cells, thus suggesting a fusion blockade. Mutations of the FP also resulted in reduced virus reactivity with flavivirus group-reactive antibodies, confirming earlier reports using virus-like particles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913272     DOI: 10.1016/j.virol.2009.10.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.

Authors:  Sven Verdonck; Szu-Yuan Pu; Fiona J Sorrell; Jon M Elkins; Mathy Froeyen; Ling-Jie Gao; Laura I Prugar; Danielle E Dorosky; Jennifer M Brannan; Rina Barouch-Bentov; Stefan Knapp; John M Dye; Piet Herdewijn; Shirit Einav; Steven De Jonghe
Journal:  J Med Chem       Date:  2019-06-12       Impact factor: 7.446

2.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Atomic-level functional model of dengue virus Envelope protein infectivity.

Authors:  Elizabeth A Christian; Kristen M Kahle; Kimberly Mattia; Bridget A Puffer; Jennifer M Pfaff; Adam Miller; Cheryl Paes; Edgar Davidson; Benjamin J Doranz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-24       Impact factor: 11.205

4.  Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.

Authors:  Szu-Yuan Pu; Randy Wouters; Stanford Schor; Jef Rozenski; Rina Barouch-Bentov; Laura I Prugar; Cecilia M O'Brien; Jennifer M Brannan; John M Dye; Piet Herdewijn; Steven De Jonghe; Shirit Einav
Journal:  J Med Chem       Date:  2018-07-16       Impact factor: 7.446

5.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

6.  Crystal structure of the Japanese encephalitis virus envelope protein.

Authors:  Vincent C Luca; Jad AbiMansour; Christopher A Nelson; Daved H Fremont
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

7.  Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues.

Authors:  Trevor J Pitcher; Vanessa V Sarathy; Kiyohiko Matsui; Gregory D Gromowski; Claire Y-H Huang; Alan D T Barrett
Journal:  J Gen Virol       Date:  2014-10-22       Impact factor: 3.891

8.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970

9.  Structure-based mutational analysis of several sites in the E protein: implications for understanding the entry mechanism of Japanese encephalitis virus.

Authors:  Haibin Liu; Yi Liu; Shaobo Wang; Yanjun Zhang; Xiangyang Zu; Zheng Zhou; Bo Zhang; Gengfu Xiao
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Authors:  Jorge E Osorio; Ivan D Velez; Cynthia Thomson; Liliana Lopez; Alejandra Jimenez; Aurelia A Haller; Shawn Silengo; Jaclyn Scott; Karen L Boroughs; Janae L Stovall; Betty E Luy; John Arguello; Mark E Beatty; Joseph Santangelo; Gilad S Gordon; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Lancet Infect Dis       Date:  2014-07-23       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.